Datasets - Consumption of Different Classes of Antibiotics, by Inducing Distinct Alterations of the Microbiome, May Affect the Incidence of Inflammatory Bowel Disease: a European Survey

Table 1.:The average total yearly systemic antibiotic consumption [J01, 2004-2023, 20 years] expressed in defined daily dose/1000 inhabitants/day [DID] in 30 European countries, and the consumption of antibiotic classes is described as a relative share in percentage [%] of the total systemic consumption [J01] with the IBD age-stratified incidence rates [ASIR]/100k population of 15-39 years]. The table also shows the results of the statistical analyses.Glossary: Antibiotic categories [ACT codes]: Total systemic antibiotics: J01, tetracyclines: J01A, penicillin group [all]: J01C, broad spectrum, penicillinase susceptible penicillin: J01CA, narrow spectrum, penicillinase susceptible penicillin: J01CE, narrow spectrum, penicillinase resistant, narrow spectrum penicillin: J0CF, broad spectrum, penicillinase resistant penicillin: J01CR, cephalosporines: J01D, sulfonamides: J01E, macrolides and lincomycin: J01F, aminoglycosides: J01G, quinolones: J01M, other antibiotics: J01X, which includes glycopeptides, polymyxine, steroid antibacterial, imidazole derivates, nitrofurantoin derivates, etc. Table 2.:Rank order of the incidence of IBD [ASIR 2021] and the rank order distribution of the countries with higher consumption of antibiotic classes with positive [J01A, J01CE, J01E] and the low consumption of antibiotic groups with negative statistical association [J01D, J01F, J01M]. The first 10 countries in the IBD rank order appear [bold, larger font, shaded] in the top 10 for positive association with antibiotic classes and the bottom 10 for negative association with antibiotic classes. Seven countries are identical in the antibiotic groups with a positive statistical association, and 5-8 in the low-consumption groups with a negative association and lower IBD incidence.